ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Bridging evidence and practice in heart failure care: barriers and pragmatic solutions to guideline-directed medical therapy implementation in India and other low-resource settings.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity, hospitalization, and mortality in low- and middle-income countries (LMICs). Guideline-directed medical therapy (GDMT) including angiotensin receptor-neprilysin inhibitors (ARNIs), evidence-based beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose co-transporter 2 (SGLT2) inhibitors has consistently demonstrated reductions in mortality and heart failure (HF) hospitalizations. Despite strong evidence, real-world implementation of GDMT in LMICs remains suboptimal. This article synthesizes published evidence and expert experience to identify barriers to GDMT implementation in India and comparable LMIC settings and to propose pragmatic, resource-aligned strategies to improve uptake. Relevant English-language literature (2015-2025) was identified through PubMed, Google Scholar, and guideline repositories (ESC, ACC/AHA/HFSA, CSI). Search terms included "heart failure," "GDMT," "LMIC," "India," "implementation barriers," and "pharmacist-led care." Key guidelines, randomized trials, observational studies, registries, and relevant reviews were included. Barriers span economic constraints, limited insurance coverage, high out-of-pocket costs, low health literacy, cultural beliefs, fragmented follow-up, limited access to specialized HF services, inconsistent drug availability, and clinician-level knowledge-practice gaps. Evidence from observational studies and implementation reports supports early low-dose combination GDMT, simplified titration pathways, pharmacist- and nurse-led follow-up models, task-shifting, and telemedicine-enabled monitoring as feasible strategies in LMIC settings. Bridging the evidence-practice gap for GDMT in LMICs requires coordinated, multi-level interventions tailored to resource constraints. Strengthening team-based care and aligning policy with essential HF therapies can substantially improve outcomes and equity.
Indexed as
Identifiers
42343046What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.